The circulating level of Non-coding RNA for breast cancer diagnosis

Abstract Background: The expression of non-coding RNAs were closely related to breast cancer progression. However, there were no systemic analysis of non-coding RNAs in breast cancer diagnosis of the blood circulatory system. Herein, we aimed to collect all the evidence to test the potential role of non-coding RNAs as novel biomarkers in human breast cancers. Methods: A comprehensive search strategy was used to search relevant literatures in the Web of Science, PubMed, and Embase databases from January 2012 to November 2019. The correlation of non-coding RNAs expression in serum, plasma or blood circulatory system and the diagnostic accuracy of BC markers were analyzed. The methodological quality of each study was assessed using the QUADAS-2. Statistical analysis was used the STATA (version 12.0), Meta-Disc (version 1.4) and Review Manager (version 5.3) software. Results: The present meta-analysis of the non-coding RNAs expression data of BC patients and healthy specimens’ bloodfrom 2392 patients in 24 publications (32 studies). The pooled sensitivity, specificity, and AUC values were 0.82, 0.83, and 0.89, respectively. Subgroup analyses showed that the expression of non-coding RNA (miRNA, circRNA, andlncRNA) in the blood circulatory system (including blood, plasma, and serum) of BC was more prone to be detected in TNM stage and subtype of BC group, with a high value of the sensitivity and AUC. Conclusions: The blood circulatory system (including blood, plasma, and serum) of miRNAs, circRNAs, and lncRNAs detection may be effective for diagnosing breast cancer, particularly in TNM stage, subtype of BC (ER/PgR, PR or HER2/c-erbB-2) group of breast cancer. Further studies are needed to identify the value of these non-coding RNAs as novel markers in clinical.

Download Full-text

The circulating level of Non-coding RNA for breast cancer diagnosis

10.21203/rs.2.19596/v1 ◽

2019 ◽

Author(s):

miao wang ◽

yao gu ◽

jie zhang ◽

zhaojun jia ◽

huijian wu

Keyword(s):

Breast Cancer ◽

Blood Plasma ◽

Cancer Progression ◽

Cancer Diagnosis ◽

Meta Analysis ◽

Breast Cancer Diagnosis ◽

Tnm Stage ◽

Breast Cancers ◽

Non Coding Rna ◽

Non Coding Rnas

Abstract Background: Lots of non-coding RNAs expression affected breast cancer progression. However, there were no systemic analysis of non-coding RNAs for breast cancer diagnosis in circulatory system. Herein, we aimed to collect all the evidence to test the potential role of non-coding RNAs as novel biomarker in human breast cancers. Methods: A comprehensive search strategy was used to search relevant literatures in the Web of Science, PubMed, and Embase databases from 2012 to November 2019. The correlation between non-coding RNAs in serum, plasma or blood expression and the diagnostic accuracy of BC markers were analyzed. The methodological quality of each study was assessed using the QUADAS-2. Statistical analysis was used the STATA (version 12.0), Meta-Disc1.4 and Review Manager (version 5.3) software. Results: The present meta-analysis the non-coding RNAs expression data of BC patients and healthy specimens’ bloodfrom 2392 patients in 24 publications (32 studies). The pooled sensitivity, specificity, and AUC values were 0.82, 0.83, and 0.89, respectively. Subgroup analyses showed that the expression of non-coding RNA (miRNA, circRNA, andlncRNA) in circulating (including blood, plasma, and serum) of BC was more prone to be detected in TNM stage and subtype of BC group, with a high value of the sensitivity and AUC. Conclusions: The circulating (including blood, plasma, and serum) level of miRNAs, circRNAs, and lncRNAs for breast cancer diagnosis may be effective, particularly in TNM stage, subtype of BC (ER/PgR, PR or HER2/c-erbB-2) breast cancer. Further prospective studies on the diagnostic value of non-coding RNAs from breast cancer are needed in the future.

Download Full-text

Method for breast cancer diagnosis by phase spectrophotometry of human blood plasma

10.1117/12.920906 ◽

2011 ◽

Author(s):

Ozar P. Mintser ◽

B. P. Oliinychenko

Keyword(s):

Breast Cancer ◽

Blood Plasma ◽

Cancer Diagnosis ◽

Human Blood ◽

Breast Cancer Diagnosis ◽

Human Blood Plasma

Download Full-text

PAR Genes: Molecular Probes to Pathological Assessment in Breast Cancer Progression

Pathology Research International ◽

10.4061/2011/178265 ◽

2011 ◽

Vol 2011 ◽

pp. 1-6

Author(s):

Beatrice Uziely ◽

Hagit Turm ◽

Myriam Maoz ◽

Irit Cohen ◽

Bella Maly ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Progression ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

Molecular Probes ◽

Mirror Image ◽

Binding Region ◽

Therapeutic Modalities ◽

Choice Of Treatment ◽

G Protein Coupled

Taking the issue of tumor categorization a step forward and establish molecular imprints to accompany histopathological assessment is a challenging task. This is important since often patients with similar clinical and pathological tumors may respond differently to a given treatment. Protease-activated receptor-1 (PAR1), a G protein-coupled receptor (GPCR), is the first member of the mammalian PAR family consisting of four genes. PAR1 and PAR2 play a central role in breast cancer. The release of N-terminal peptides during activation and the exposure of a cryptic internal ligand in PARs, endow these receptors with the opportunity to serve as a “mirror-image” index reflecting the level of cell surface PAR1&2-in body fluids. It is possible to use the levels of PAR-released peptide in patients and accordingly determine the choice of treatment. We have both identified PAR1 C-tail as a scaffold site for the immobilization of signaling partners, and the critical minimal binding site. This binding region may be used for future therapeutic modalities in breast cancer, since abrogation of the binding inhibits PAR1 induced breast cancer. Altogether, both PAR1 and PAR2 may serve as molecular probes for breast cancer diagnosis and valuable targets for therapy.

Download Full-text

The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women

Scientific Reports ◽

10.1038/s41598-020-79285-z ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Tamina Elias-Rizk ◽

Joelle El Hajj ◽

Evelyne Segal-Bendirdjian ◽

George Hilal

Keyword(s):

Breast Cancer ◽

Cancer Progression ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

Breast Disease ◽

Risk Category ◽

Limiting Factor ◽

Morphological Variations ◽

Image Guided ◽

Potential Marker

AbstractBreast cancer is the most common cancer in women worldwide. Minimally invasive percutaneous image-guided biopsies are the current cornerstone in the diagnosis of breast lesions detected on mammography/ultrasonography/MRI or palpable clinically. However, apparently benign breast disease seen on benign biopsies is a limiting factor for diagnosis and a risk factor of breast cancer especially in the high-risk category patients. Hypothesizing that molecular changes often occur before morphological variations, the levels of the LncRNA H19 were measured in anonymous tissues obtained from 79 women’s image guided breast biopsies, and correlated with cancer progression and aggressiveness. Using a double-blinded approach, H19 might be attributed an interesting role of a more sensitive biomarker in core breast biopsies, independently of the radiological/clinical classification and distant from the clinical management. We established different thresholds for H19 levels in normal versus proliferative, versus malignant tissues. Additionnally, H19 could act as an intra-group risk marker categorizing the biopsies in normal versus benign, versus precancerous breast tissue, and as a prognostic factor in cancerous lesions discriminating aggressive versus nonaggressive lesions. Our study suggests that the lncRNA H19 could be a potential marker for breast cancer diagnosis, prognosis and risk management.

Download Full-text

Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients

Journal of Oncology ◽

10.1155/2019/6425708 ◽

2019 ◽

Vol 2019 ◽

pp. 1-8 ◽

Cited By ~ 7

Author(s):

Laith N. AL-Eitan ◽

Doaa M. Rababa’h ◽

Mansour A. Alghamdi ◽

Rame H. Khasawneh

Keyword(s):

Breast Cancer ◽

Abc Transporter ◽

Cancer Progression ◽

Cancer Diagnosis ◽

Estrogen Receptor Status ◽

Breast Cancer Diagnosis ◽

Lymph Node Status ◽

Axillary Lymph ◽

Breast Cancer Patients ◽

Abc Transporter Genes

Breast cancer pharmacogenetics is increasingly being explored due to chemotherapy resistance among certain classes of patients. The ATP binding cassette (ABC) transporter genes have been previously implicated in breast cancer progression and drug response. In the present study, single nucleotide polymorphisms (SNPs) from the ABCC1, ABCC2, ABCB1, and ABCG2 genes were screened in breast cancer patients and healthy volunteers from the Jordanian-Arab population. Only the ABCB1 SNPs showed a significant association with BC in Jordanian-Arab patients, and the ABCB1 SNP rs2032582 exhibited a strong genotypic association with BC. With regard to the clinical characteristics of BC, the ABCC2 SNPs rs2273697 and rs717620 were found to be significantly associated with age at breast cancer diagnosis and breastfeeding status, while the ABCB1 SNP rs1045642 was significantly associated with age at breast cancer diagnosis. In terms of pathological characteristics, the ABCC1 SNP rs35628 and the ABCB1 SNP rs2032582 were significantly associated with tumor size, the ABCC2 SNP rs2273697 was significantly associated with estrogen receptor status, and the ABCG2 SNP rs2231142 was significantly associated with axillary lymph node status. In this current study, we assume that significant genetic variants within the ABC superfamily may increase the risk of breast cancer among Jordanian women. Furthermore, these variants might be responsible for worse BC prognosis.

Download Full-text